There is increasing use of fertility medications for ovulation induction and ovarian stimulation for in-vitro fertilization in the treatment of female infertility. In this review, recent literature regarding the association between fertility medication and cancer risk is reviewed.
INTRODUCTION
With approximately 9% of the population experiencing infertility, an increasing number of couples are seeking fertility treatment. The use of in-vitro fertilization (IVF) has steadily risen, contributing to 1.5% of live births in the United States, and adding to those pregnancies resulting from ovulation induction and superovulation [1] . Consequently, concerns exist regarding long-term risks of fertility medications causing cancer, as despite their multiple modes of action, all can induce multiple ovulation and alter steroidogenesis [2] . Moreover, some cancers, including female reproductive and breast cancers, are hormone-dependent, offering a physiological mechanism behind an association between fertility medication use and cancer risk [3] . Nevertheless, although some epidemiologic studies have also suggested such a link, most others offer conflicting results often difficult to interpret.
Studying cancer risk in infertile couples poses several challenges. Several conditions, including anovulation, endometriosis and nulliparity, accompany infertility and themselves increase the risk of cancer. In addition, most of these cancers are rare and tend to occur several years after the time of fertility treatment, making proof of causal relationship difficult. Most studies are case-control and cohort studies because of rare disease outcomes, but introduce selection and recall biases, respectively [4] . In particular, older studies are limited by short-term follow-up, confounding factors, improper controls and multiple causes and treatments of infertility.
Although limitations exist, recent studies have improved knowledge through better study design, including using long-term follow-up, identifying type of infertility and method of treatment, selecting appropriate controls and assessing specific individuals
OVARIAN CANCER
Ovarian cancer is a rare but often fatal disease, accounting for 3% of all annual cancer diagnoses in women. This complex, multifactorial disease is often diagnosed at a late stage, as effective screening techniques for early disease detection do not yet exist. Risk factors for invasive ovarian cancer include nulliparity, infertility, late-onset menopause, family history and genetic susceptibility; whereas factors protective against disease are multiparity, breastfeeding and oral contraceptive use [5, 6] . Each of these factors must be considered when examining the mechanistic relationship between ovarian cancer and the use of fertility medications.
Uninterrupted ovulation causing repeated ovarian epithelial surface damage underlies the 'incessant ovulation theory' [2, 7] , based upon the theory that factors decreasing lifetime ovulation rates, such as multiparity, concomitantly reduce ovarian cancer risk. Conversely, the use of fertility medications could increase ovarian cancer risk by promoting polyfollicular ovulation [7] . This theory has been questioned by recent data that serous ovarian tumors can originate from the fallopian tube rather than the ovary itself [8] . An alternate mechanism underlying the relationship between fertility treatment and ovarian cancer is the 'elevated gonadotropin level' theory, which postulates that elevated gonadotropin levels resulting from fertility medications stimulate the ovarian epithelium and induce malignant changes [9] .
INVASIVE OVARIAN CANCER
Although studies examining the relationship between fertility medication use and ovarian cancer risk show mixed results, most studies do not demonstrate a significant increase in risk [10,11,12 & 
,13
& , [14] [15] [16] [17] . In the 1990s, two studies found an association between fertility medication use and ovarian cancer [18, 19] but were limited by specific disease characteristics, such as low prevalence and late onset (i.e. 7th decade of life), study design (i.e. inappropriate use of fertile controls, limited length of follow-up, lack of control for parity and other diseases) and lack of stratification by type and duration of fertility medication use.
Most recent studies and systematic reviews show no overall association between fertility medication use and invasive ovarian cancer when using a subfertile control group or the general population [10,11,12 ,13 & , [14] [15] [16] [17] , although some studies finding such an association used the general population rather than a subfertile group as controls. Asante et al. [11] and Brinton et al. [20] did not find an association between ovarian cancer and fertility treatment when using a subfertile control group, even when women had undergone at least four cycles of IVF [20] . A meta-analysis of nine cohort studies including 109 969 patients compared the ovarian cancer risk in women receiving fertility treatment with that in an infertile reference group and the general population. The ovarian cancer risk in women receiving fertility treatment was increased compared to the general population [ 
KEY POINTS
Data on the association between use of fertility medications and cancer are limited and come principally from observational cohort and case-control studies with several methodological issues.
Although infertility per se is a risk factor for a number of female cancers including breast, endometrial and invasive ovarian cancer, there are insufficient data to suggest a meaningful association between fertility medication use and these cancers.
Several studies have suggested a small increased risk of developing borderline ovarian cancer; however, the absolute increased risk is small and these indolent tumors have a favorable prognosis.
There is insufficient evidence to suggest an association between fertility medication use and cancers of the cervix, thyroid and colon or melanoma.
Additional studies with longer follow-up are needed to determine whether unique subgroups of women are at increased risk of developing cancer following fertility treatment.
found no association between invasive ovarian cancer and IVF compared to that in the population [standardized incidence ratio (SIR): 0.96-1.18, not significant (NS)]. Paradoxically, IVF patients had a decreased risk of all cancers (SIR: 0.78, 95% CI 0.73-0.83), although a study limitation was a short average follow-up time of only 5 years [12 & ]. Another population-based cohort study of parous women in Norway found no significant association between IVF and ovarian cancer risk (hazard ratio: 1.56, 95% CI 0.94-2.60). An increased risk of ovarian cancer occurred in IVF patients who had only one child but no longer existed after adjusting for multiple comparisons [13 & ]. Despite these reassuring findings, two cohort studies show that women failing to conceive after clomiphene citrate therapy have an increased risk for ovarian cancer [14, 15] , warranting further investigation of this subgroup of women.
Two recent studies have assessed risk of ovarian cancer in BRCA mutation carriers undergoing fertility treatment, as this high-risk group may also be more likely to undergo fertility treatment for fertility preservation or diminished ovarian reserve [22] . Both studies are small in size but reassuring [23, 24 & ]. One cohort study of 1073 BRCA mutation carriers, of which 164 (15%) patients received fertility treatment, showed no association between fertility treatment and ovarian cancer, regardless of type of fertility treatment [24 & ]. Another matched casecontrol study of 941 pairs of BRCA mutation carriers with and without a cancer diagnosis found no significant relationship between fertility medication use and subsequent risk of ovarian cancer [23] .
BORDERLINE OVARIAN CANCER
Borderline ovarian tumors (i.e. tumors of low malignant potential) are noninvasive, indolent tumors that differ from invasive ovarian cancer in having an excellent prognosis with a 5-year survival rate of 95% and occurring more commonly in reproductive-aged women. These tumors are also rare, with an incidence of 1.8-4.8 per 100 000 women years, making the absolute versus relative risk of this disease an important consideration [25] .
Unlike invasive ovarian cancer, studies have found a more consistent association between borderline ovarian cancer and use of fertility medication. Early studies, including a cohort study, demonstrated a significant association between borderline ovarian tumors and women receiving fertility treatment versus those not receiving treatment (SIR: 3.3, 95% CI 1.1-7.8), based on five cases of borderline ovarian cancer [18] . Larger recent studies using infertile controls have found similar results [10, 26] . A Dutch cohort study of 19 861 women undergoing IVF versus 6604 subfertile women with an average follow-up of 14.7 years found an increased risk of borderline ovarian tumors in the former women, adjusting for age, parity and fertility diagnosis (SIR: 1.79, 95% CI 1.16-2.56) [10] . Another cohort study found a similarly increased rate of borderline ovarian cancer in women who received IVF, controlling for confounders (hazard ratio: 2.66, CI 1.2-5.04). Unlike its invasive counterpart, borderline ovarian cancer has not been associated with parity, endometriosis or prior surgery [26] .
Conversely, not all evidence demonstrates an association between fertility treatment and borderline ovarian tumors [11,27 & ,28] . A recent casecohort study of 96 545 Dutch subfertile women, including 142 cases of borderline ovarian tumors, found no association between all subtypes of ovarian borderline cancer and fertility medication use (RR: 1.00, 95% CI 0.67-1.51), which was consistent across fertility treatment cycles and follow-up duration [27 & ]. An increased association between serous borderline ovarian tumors and progesterone use currently lacks biologic explanation.
Although a large systemic review shows heterogeneity of data [16] , a possible link between borderline ovarian tumors and fertility medications cannot be ignored. Despite possible surveillance bias, most borderline ovarian tumors have been diagnosed up to 7-9 years after fertility treatment [26] , raising concern about such an association, although the absolute increased disease risk is extremely small, given the low incidence of disease.
OTHER GYNECOLOGIC CANCERS

Endometrial cancer
Endometrial cancer is the most common cancer of the female reproductive track and the fourth most common cancer diagnosed in women. Risk factors for endometrial cancer include polycystic ovarian syndrome (PCOS), anovulatory infertility, obesity, age, family history and tamoxifen use [29] . Type I endometrial cancer is hormone-dependent, with unopposed estrogen increasing risk and progesterone having a protective effect. Several recent studies have examined the relationship between endometrial cancer and the use of fertility mediations, but are limited by small sample size, short follow-up and several confounding factors, such as ovulatory dysfunction and PCOS.
Although some studies demonstrate an increased risk in endometrial cancer in women using specific fertility medications [ [14] . A retrospective cohort study of 12 193 women evaluated for infertility found no significant association between use of any fertility treatment and endometrial cancer risk [31] . These findings agree with a meta-analysis that found an increased risk in endometrial cancer in women undergoing IVF, but only when compared to the general population, not the group of subfertile women [17] . These studies again emphasize the importance of using infertile women as controls to better adjust for preexisting endometrial cancer risk factors that may exist in infertile women.
Cervical cancer
Several studies assessing the risk of cervical cancer following fertility medication use have consistently shown no increased risk of cervical cancer compared to both the general population and infertile patients as controls [13 & ,14,17,21 & ] . A subset of studies have found a decreased incidence of cervical cancer in IVF patients [20, 32] , although the mechanism behind this phenomenon is unclear but perhaps related to better access to care with more frequent cervical cytology screening in women undergoing fertility treatment.
Breast cancer
Breast cancer is the most common malignancy in women worldwide, affecting one in eight women. Factors that increase the risk for breast cancer include exogenous sex steroid exposure and increased endogenous sex steroid actions through early menarche and late menopause in combination with nulliparity [3] . Fertility treatments can temporarily induce supra-physiological circulating sex steroid levels and therefore could theoretically increase breast cancer risk. Studies to date, however, have not shown a consistent relationship between breast cancer risk and fertility treatment, often suffering from the same shortcomings of other cancer-related studies, particularly short-term follow-up and other confounding variables.
Most recent studies have not shown an association between breast cancer and fertility medication use when comparing women undergoing fertility treatment to both a general population and infertile controls [12 & ,33 && ,34-36] . Although two recent studies found an association of fertility treatment with breast cancer, the increased risk was modest [37, 38] . A recent cohort study of 19 158 IVF patients and 5950 non-IVF-related patients receiving fertility treatment compared breast cancer risk with the general population with a median follow-up of 21.1 years. No increased risk of breast cancer occurred in IVF patients compared to either the general population (SIR: 1.01, 95% CI 0.93-1.09) or non-IVF-related patients receiving fertility treatment (hazard ratio: 1.01, 95% CI 0.86-1.19) [33 && ]. These data agree with a recent meta-analysis of eight cohort studies that comprised 1554 332 women and 14 961 breast cancer cases and demonstrated no increased risk of breast cancer in IVF patients versus the general (RR: 0.91, 95% CI 0.74-1.11) or infertile female population (RR: 1.02, 95% CI 0.88-1.18) [37] . Apart from IVF, a cohort study of 12 193 infertile women followed for 30 years found no increased risk of breast cancer after clomiphene citrate (hazard ratio: 1.05, 95% CI 0.9-1.22) or gonadotropin (hazard ratio: 1.14, 95% CI 0.89-1.44) exposure compared to infertile controls [34] .
Nevertheless, some types of women may be at increased risk for breast cancer following fertility treatment, specifically those individuals who initiate such treatment at a young age [36, 39, 40] or undergo a high cumulative number of clomiphene citrate cycles [34, 40] .
OTHER MALIGNANCIES
Thyroid cancer
Thyroid disorders including cancer are more common in women than men, with a peak incidence during the reproductive years [41] . Furthermore, the presence of estrogen receptors in thyroid cancers [42] implicates sex steroid action with thyroid cancer. With the rising incidence of thyroid cancer in the United States, perhaps from improved surveillance and diagnostic testing [43] , several studies have investigated the relationship between fertility medication use and thyroid cancer. Most studies have found no such association [44, 45] .
In a retrospective cohort of 8422 women evaluated for infertility, neither clomiphene citrate (RR: 1.42, 95% CI 0. 
Colorectal cancer
In a large cohort study [46] , clomiphene citrate use did not significantly increase the risk of colon cancer (RR: 0.83; 95% CI 0.4-1.9). Furthermore, in a retrospective cohort study [ 
Melanoma
Given several studies examining the occurrence of malignant melanoma following use of fertility treatments, most have not shown an increased risk of this disease [46,50 & ] . One retrospective cohort study from Australia [51] found that women giving birth following IVF had an increased rate of invasive melanoma versus women who failed to conceive after IVF, based on 139 invasive melanoma cases (hazard ratio: 3.61; 95% CI 1.79-7.26). There was, however, no increased risk in women receiving non-IVF-related fertility treatment (hazard ratio: 1.39; 95% CI 0.88-2.20). In another study, fertility treatment was not associated with malignant melanoma, except for an increased risk following use of gonadotrophins or gonadotropin-releasing hormone in parous women [52] . Finally, the use of clomiphene citrate has been associated with increased risk of melanoma in some [47 && ,53] but not all [46, 52] studies.
CONCLUSION
Data on the association between fertility treatments and cancer risk are limited, being mostly derived from observational cohort or case-control studies. Many such studies have methodological problems including small sample size, heterogeneous populations and treatments, multiple covariables and short-term follow-up. In addition, infertility per se is a risk factor for certain cancers including those of the breast, ovary and uterus. Recent studies have attempted to address these limitations by investigating more homogeneous populations, employing longer follow-up intervals, assessing cancer risk in low-risk versus high-risk individuals and using infertile women as appropriate controls. Overall, most studies show that fertility treatments do not increase the risks of invasive ovarian cancer, malignant melanoma or cancers of the endometrium, cervix, breast, thyroid or colon. There is, however, limited evidence that the use of fertility treatments may modestly increase the risk of borderline ovarian cancer, although this risk is small in absolute terms and such an ovarian cancer with low-malignant potential, if found, has a favorable prognosis.
